📊 GOSS Key Takeaways
Is Gossamer Bio, Inc. (GOSS) a Good Investment?
Gossamer Bio exhibits severe financial distress with negative stockholders' equity of -$161.5M indicating technical insolvency. Collapsing revenues (-57.7% YoY to $17M) combined with $38.7M annual operating losses generate a runway of approximately 12-13 months at current cash levels, creating imminent solvency risk absent dramatic operational or capital structure improvements.
Fundamentals show steep revenue contraction, persistently large operating losses, and negative stockholders’ equity, resulting in extremely weak margins and ROA. While the current ratio is acceptable and there is no long‑term debt, cash is small relative to the annual operating cash burn, implying urgent financing needs and elevated dilution/distress risk.
Why Buy Gossamer Bio, Inc. Stock? GOSS Key Strengths
- Maintains $41M cash balance providing short-term liquidity cushion
- Zero long-term debt reduces refinancing risk in near term
- Current and quick ratios of 2.20x provide surface-level short-term liquidity coverage
- No long-term debt reduces fixed obligations
- Current ratio of 2.64x provides short-term liquidity cushion
- Asset-light model with minimal capex requirements
GOSS Stock Risks: Gossamer Bio, Inc. Investment Risks
- Negative stockholders' equity of -$161.5M represents technical insolvency and balance sheet deterioration
- Revenue collapsed 57.7% YoY indicating severe business contraction or major partnership loss
- Operating cash burn of $38.7M annually with only $41M cash implies 12-13 month runway before capital exhaustion
- Net margin of -275.2% and operating margin of -264.6% demonstrate extreme unprofitability with no visible path to profitability
- Potential requirement for immediate capital raise, restructuring, or acquisition at severe equity dilution
- Negative equity with sustained heavy losses and -353% FCF margin
- Revenue down 57.7% YoY, indicating weak/volatile demand or one-time revenues
- High cash burn versus $37.7M cash suggests imminent funding/dilution risk
Key Metrics to Watch
- Monthly cash burn rate and updated cash runway projections
- Revenue stabilization and pipeline progression in biopharmaceutical development
- Strategic partnerships, licensing deals, or capital raise announcements
- Cost reduction initiatives and workforce adjustments
- Cash runway (cash & equivalents vs operating cash outflow)
- Revenue trend and recurrence from collaborations/products
Gossamer Bio, Inc. (GOSS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.20x current ratio provides a solid financial cushion.
GOSS Profit Margin, ROE & Profitability Analysis
GOSS vs Healthcare Sector: How Gossamer Bio, Inc. Compares
How Gossamer Bio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Gossamer Bio, Inc. Stock Overvalued? GOSS Valuation Analysis 2026
Based on fundamental analysis, Gossamer Bio, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Gossamer Bio, Inc. Balance Sheet: GOSS Debt, Cash & Liquidity
GOSS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Gossamer Bio, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.18 indicates the company is currently unprofitable.
GOSS Revenue Growth, EPS Growth & YoY Performance
GOSS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $9.9M | -$36.6M | $-0.16 |
| Q3 2025 | $9.5M | -$23.5M | $-0.10 |
| Q2 2025 | $11.5M | $7.3M | $0.03 |
| Q1 2025 | N/A | -$36.6M | $-0.16 |
| Q3 2024 | N/A | -$23.5M | $-0.10 |
| Q2 2024 | N/A | $7.3M | $0.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Gossamer Bio, Inc. Dividends, Buybacks & Capital Allocation
GOSS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Gossamer Bio, Inc. (CIK: 0001728117)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GOSS
What is the AI rating for GOSS?
Gossamer Bio, Inc. (GOSS) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GOSS's key strengths?
Claude: Maintains $41M cash balance providing short-term liquidity cushion. Zero long-term debt reduces refinancing risk in near term. ChatGPT: No long-term debt reduces fixed obligations. Current ratio of 2.64x provides short-term liquidity cushion.
What are the risks of investing in GOSS?
Claude: Negative stockholders' equity of -$161.5M represents technical insolvency and balance sheet deterioration. Revenue collapsed 57.7% YoY indicating severe business contraction or major partnership loss. ChatGPT: Negative equity with sustained heavy losses and -353% FCF margin. Revenue down 57.7% YoY, indicating weak/volatile demand or one-time revenues.
What is GOSS's revenue and growth?
Gossamer Bio, Inc. reported revenue of $17.0M.
Does GOSS pay dividends?
Gossamer Bio, Inc. does not currently pay dividends.
Where can I find GOSS SEC filings?
Official SEC filings for Gossamer Bio, Inc. (CIK: 0001728117) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GOSS's EPS?
Gossamer Bio, Inc. has a diluted EPS of $-0.20.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GOSS a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Gossamer Bio, Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GOSS stock overvalued or undervalued?
Valuation metrics for GOSS: ROE of N/A (sector avg: 15%), net margin of -275.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GOSS stock in 2026?
Our dual AI analysis gives Gossamer Bio, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GOSS's free cash flow?
Gossamer Bio, Inc.'s operating cash flow is $-38.7M, with capital expenditures of $0.0. FCF margin is -228.4%.
How does GOSS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -275.2% (avg: 12%), ROE N/A (avg: 15%), current ratio 2.20 (avg: 2).